If you are thinking about starting a family — or simply want to understand what nicotine is doing to your body — the research on women’s reproductive health is eye-opening.
Nicotine cessation messaging has historically been aimed at men. The imagery, the statistics, the warnings — they tend to center on lung cancer and heart disease, framed through a male lens. But the impact of nicotine on the female body is distinct, significant, and far less discussed.
This matters particularly for women who vape or use nicotine pouches — products that are often perceived as safer than cigarettes and therefore not associated with the same health urgency. The delivery method may differ. The consequences for reproductive health are remarkably similar.
Female fertility is fundamentally about egg quality and ovarian reserve — the number of viable eggs remaining. Unlike men, who continuously produce sperm, women are born with all the eggs they will ever have. Damage to that supply is not replaced.
A 2024 review published in the Journal of Applied Toxicology found that nicotine can cause oxidative stress, hormonal imbalance, disruption of ovarian function, and direct toxic effects on oocyte development. Research consistently shows that women who use nicotine have lower levels of anti-Mullerian hormone (AMH) — the most reliable marker of ovarian reserve — compared to non-users. Lower AMH means fewer viable eggs available for conception. Research cited by the American Society for Reproductive Medicine also shows that follicle-stimulating hormone (FSH) levels are significantly elevated in nicotine users — a sign the body is working harder to stimulate ovulation as ovarian function declines.
The American Society for Reproductive Medicine, in its 2024 committee opinion on tobacco and fertility, noted that chemicals in nicotine products appear to accelerate follicular depletion — essentially speeding up the biological clock. Women who use nicotine experience menopause an average of one to four years earlier than non-users.
American Society for Reproductive Medicine Committee Opinion, 2024. Tobacco or Marijuana Use and Infertility. Fertility and Sterility, 121(4), 589–603.
Nicotine interferes with estrogen metabolism in multiple ways. Research shows that nicotine inhibits aromatase — the enzyme responsible for estrogen production — and accelerates the breakdown of estrogen in the body. Multiple studies have found that estrogen levels during the luteal phase are significantly lower in nicotine users compared to non-users, with the magnitude varying across studies.
Lower estrogen disrupts ovulation, affects uterine lining development, and can make conception significantly harder. It also explains why women who use nicotine report more irregular cycles and why quitting often normalizes menstrual patterns within a few months.
“Nicotine does not just affect whether you can get pregnant. It affects the hormonal environment that governs your entire reproductive cycle.”
There is also a bidirectional relationship worth understanding: estrogen affects how women experience nicotine. Research shows that cravings and withdrawal are stronger during certain phases of the menstrual cycle, particularly when estrogen is higher. This is one reason why quitting can feel harder for women than men, and why a medication-based approach is particularly valuable — it addresses the receptor-level dependence that hormone fluctuations intensify.
The evidence here is particularly clear. Nicotine use is associated with longer time-to-conception, higher rates of miscarriage, and increased risk of ectopic pregnancy. Animal studies show that nicotine exposure can delay embryo implantation and affect uterine receptivity — the window during which a fertilized egg can successfully attach.
For women pursuing IVF, the data is especially relevant. Studies consistently show that women who use nicotine produce fewer mature eggs in response to ovarian stimulation, have lower fertilization rates, and have lower rates of successful implantation compared to non-users. Fertility specialists universally recommend quitting nicotine — in all forms — before beginning fertility treatment.
The good news: most of these effects are substantially reversible with cessation. Fertility specialists generally recommend allowing at least three months after quitting before trying to conceive, giving the body time to rebalance hormones, improve egg quality, and normalize ovarian function.
Nicotine is a vasoconstrictor — it narrows blood vessels throughout the body, including the tiny capillaries that supply oxygen and nutrients to skin. Over time, this reduced blood flow accelerates collagen breakdown and impairs the skin’s ability to repair itself.
The visible effects are well documented: deeper lines around the mouth from repeated pursing, uneven skin tone from reduced circulation, and a dullness that comes from cells being chronically oxygen-deprived. Nicotine also generates free radicals that damage collagen and elastin directly, accelerating the structural changes associated with aging skin. These effects apply to vaping and pouches, not just cigarettes — the vasoconstriction is nicotine-driven, not smoke-driven.
No supplement, skincare routine, or fertility protocol fully offsets the impact of ongoing nicotine use on the female body. The most effective thing a woman can do for her hormonal health, fertility, and skin is to quit — and to quit completely, not just reduce.
Varenicline, the prescription medication Respiro is built around, has the strongest clinical evidence of any cessation treatment. It works by binding to the same nicotine receptors in the brain, quieting cravings and withdrawal, and blocking the reward if you slip. The 12-week quit rate in clinical trials is approximately 44% — more than triple cold turkey. It is safe, generic, and accessible online in minutes.
Get a varenicline prescription online in minutes. No doctor visit. No waiting room. Launching Q2 2026.
Get Early Access — 60 Seconds →